A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

CME e-Learning

CME E-Learning Modules
 
City of Hope's Department of Continuing Medical Education offers accredited e-Learning courses/programs in addition to conferences and symposiums.
 
Modules
 

How the Experts Treat Kidney Cancer

Release date: November 22, 2011
Estimated time to complete activity: 1.25 hours

To obtain CME credit: 
 
  • Complete the evaluation form
  • Submit to CME department via
    • Fax - 626-301-8939 or
    • Email - cme@coh.org or
    • Standard mail - 1500 E. Duarte Rd., Building 94, Duarte, CA 91010
 
  • Questions:626-256-4673, ext. 65622
 
Additional Resources:

Reading List

In the US, renal cell cancer (RCC) accounts for about 3% of all adult cancers. NCI data indicate that an estimated 58,000 new cases of kidney cancer were diagnosed in 2010, and approximately 13,000 Americans died of the disease. Surgery to remove the affected kidney is the most common initial treatment for all stages of kidney cancer. However, regionally advanced or metastatic cases account for approximately half of all new cases. Historically survival rates for these patient populations have been about 20%. This poor prognosis combined with modest efficacy and high toxicity associated with currently available therapies for RCC has necessitated and resulted in the development of newer targeted therapies in order to improve outcome in these patient groups. This activity has been designed to provide the health care professional with the most current clinical and investigative data pertaining to new less invasive surgical techniques for the primary management of RCC and the expanding role of emerging multi-targeted therapies for patients with regionally advanced or metastatic RCC.

Upon successful completion of this activity, the learner should be better able to:
  • Review "traditional" and less invasive surgical techniques for the management of kidney cancer
  • Examine how new multi-targeted therapies beneficially impact the management of metastatic kidney cancer
  • Discuss current therapeutic approaches to the treatment of metastatic kidney cancer
  • Describe the multidisciplinary treatment paradigm for the treatment of kidney cancer

 

This activity has been designed to meet the needs of medical oncologists, urologists, internists and allied health care providers who treat patients with kidney cancer.
 

City of Hope is accredited by the Accreditation Council for Continuing Medical education to provide continuing medical education for physicians.
City of Hope designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The following may apply CME Category 1 credit for license renewal:
 
  • Registered Nurses: Nurses may report up to 1.25 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). CME may be noted on the license renewal application in lieu of a BRN provider number.
  • Physician’s Assistants:The National Commission on certification of Physicians Assistants states that AMA accredited Category 1 courses are acceptable fro CME requirements for recertification.
  •  
  • To receive CME credit, it is necessary to complete the post test & evaluation form. For more information,please click here.
  •  
  • City of Hope has implemented policies and procedures to be in strict compliance with current ACCME Standards of Commercial Support requiring disclosure and resolution conflicts of interest.

 

Faculty Disclosure:
As part of these new commercial guidelines, we are required to disclose if Faculty , Presenters, Authors, Planners, CME Committee Members, Course Directors and / or Moderators have any real or apparent vested commercial interest(s) in both those companies whose products may be discussed/described during the course of the activity and in those companies who may be acting as commercial supporters of the activity.

Disclosure of Off-Label Use:
This activity may contain discussion of published and/or investigational uses of agents that are not approved/indicated by the US Food and Drug Administration (FDA).

 
 
Education and Training
As one of only a select few National Cancer Institute-designated Comprehensive Cancer Centers in the country, City of Hope integrates all aspects of cancer research, treatment and education. We offer a range of programs serving students, post-doctoral trainees, health and medical professionals.

City of Hope’s Irell & Manella Graduate School of Biological Sciences equips students with the skills and strategies to transform the future of modern medicine.
City of Hope has a long-standing commitment to Continuing Medical Education (CME), sharing advances in cancer research and treatment with the health-care community through CME courses such as conferences, symposia and other on and off campus CME opportunities for medical professionals.
Local and national conferences, in-depth educational training and a certification program provide both current and aspiring health professionals opportunities to further their knowledge in their fields of interest.
 
 
City of Hope offers a range of programs and services, such as Graduate Medical Education & Clinical Training, that serve students, post-doctoral trainees, medical professionals and staff.
The goal of the Postdoctoral Training Office is to ensure the postdoctoral experience at City of Hope is rewarding and meaningful to all participants.
NEWS & UPDATES
  • Eleven years ago, lymphoma patient Christine Pechera began the long road toward a cancer-free life. She had been diagnosed with non-Hodgkin lymphoma and told by doctors elsewhere that her lifespan likely would be measured in months, not years. Refusing to give up, she came to City of Hope for a second opinion. ...
  • Brain surgery is not for the faint of heart. It takes courage, as well as curiosity and compassion. The truly great surgeons also have a desire to find new, and better ways, of healing the brain. Enter Behnam Badie, M.D., chief of neurosurgery at City of Hope. Now a pioneer in brain tumor treatment, Badie enter...
  • Elizabeth Budde, M.D., Ph.D., wants to encourage infighting. She aims to turn the immune system on itself — to the benefit of patients with acute myeloid leukemia, or AML. AML arises when abnormal white blood cells grow out of control, amassing in the bone marrow and interfering with normal blood cell developme...
  • Six, to date; more soon. Outpatient bone marrow transplants, that is. Finding new ways to deliver quality care with the greatest benefit is a priority for a patient-centered institution like City of Hope. For example, not every bone marrow transplant patient needs to check into the hospital for treatment. In fa...
  • The best measure of success in the fight against cancer is in lives saved and families intact, in extra days made special simply because they exist. Yuman Fong, M.D., chair of the Department of Surgery at City of Hope, understands what precedes that special awareness. When cancer strikes, one minute a person ma...
  • In cancer, expertise matters. So do survival rates, patient safety, patient services and many other factors. City of Hope understands this, as does U.S.News & World Report. The magazine’s 2014-2015 list of best hospitals for cancer once again includes City of Hope, ranking the institution 12 out of 900 elig...
  • At 29, Kommah McDowell was a successful young professional engaged to be married to her best friend. She worked in the financial services sector and kick-boxed to keep in shape and to relax. Then came the diagnosis of triple-negative inflammatory breast cancer, a rare and very aggressive form of breast cancer. ...
  • The well-known drug tamoxifen might not always be the best choice for premenopausal women who have undergone treatment for breast cancer and face a heightened risk of recurrence. A new study suggests that the aromatase inhibitor exemestane, or Aromasin, works slightly better than tamoxifen in preventing cancer ...
  • At age 44, Bridget Hanchette, a mother of three from La Crosse, Wisconsin, was diagnosed with grade IV glioblastoma, the most aggressive type of malignant brain tumor. The cancer grows and spreads quickly, making it difficult to treat. Most patients with this diagnosis are not given much hope, but Hanchette’s i...
  • Survival rates for childhood cancer have improved tremendously over the past few decades, but postcancer care hasn’t always kept up. More children than ever are now coping with long-term complications and side effects caused by their disease and treatment — one of those being learning difficulties. A new ...
  • When Sheldon Querido, a retired manufacturer’s representative, was diagnosed with bladder cancer, his doctor told him that he’d need to have his bladder removed – and that he’d have to wear an external urine-collection bag for the rest of his life. “My first response was ‘I donR...
  • To stop smoking, two approaches might be better than one. A new study has found that using the medication varenicline, or Chantix – along with nicotine patches – was more effective than the medicine alone in helping people quit. The study, conducted by Stellanbosch University in Cape Town, South Africa, and pub...
  • John Cloer was three months shy of his third birthday in 2004 when he was diagnosed with acute lymphoblastic leukemia. For the next three and a half years, he received chemotherapy at City of Hope, finally obtaining long-term remission. His parents Bill and Gina, along with John and his younger brother Steve, r...
  • News about the risks or benefits of widespread cancer screening seem to arrive daily – 3D mammography for breast cancer, CT scans for lung cancer, PSA tests for prostate cancer and now pelvic exams for some women’s cancers. Missing in the headlines is a reflection of how cancer detection is evolving. Today’s ca...
  • Adults with sickle cell disease soon may have a new treatment option: bone marrow transplants. Children with sickle cell disease have been treated successfully with transplantation of bone marrow, more officially known as hematopoietic stem cells, from other people. But the procedure has been less successful in...